Total trials
183
Active
23
Phase 3
16
Total enrollment
44,705
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Doxofylline | — | — | — | — | — | 1 | |
| Sitagliptin | — | — | — | — | — | 2 | |
| Lithium Carbonate | — | — | — | — | — | 1 | |
| Up-front Chemotherapy | — | — | — | — | — | 1 |
Next readouts
- 2025-09
- 2025-12
- 2027-12-01
- 2028-02-28
Top conditions
- Hepatocellular Carcinoma7
- COPD7
- Lung Cancer4
- Colorectal Liver Metastases4
- Childhood Obesity4
- Periodontitis4
- Pneumonia4
- Chronic Obstructive Pulmonary Disease4
Frequently asked questions about University of Milan
- How many clinical trials does University of Milan have on ClinicalTrials.gov?
- University of Milan is listed as the lead sponsor on 183 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Milan's trials are in Phase 3?
- 16 of University of Milan's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University of Milan focus on?
- University of Milan's most-studied conditions on ClinicalTrials.gov are Hepatocellular Carcinoma, COPD, Lung Cancer, Colorectal Liver Metastases, Childhood Obesity.
- When are University of Milan's next clinical trial readouts?
- University of Milan has 4 upcoming primary-completion readouts tracked here; the soonest is “Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment”, expected around 2025-09.